Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Shionogi USA
IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients
October 16, 2024
From
Shionogi USA
Via
Business Wire
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024
September 04, 2024
From
Shionogi USA
Via
Business Wire
Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Including Recent Changes to Study Protocol to Increase Access for Participants and Families
July 18, 2024
From
Shionogi USA
Via
Business Wire
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
June 03, 2024
From
Shionogi USA
Via
Business Wire
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
May 10, 2024
From
Shionogi USA
Via
Business Wire
ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
April 18, 2024
From
Shionogi USA
Via
Business Wire
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
February 09, 2024
From
Shionogi USA
Via
Business Wire
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs
February 05, 2024
From
Shionogi USA
Via
Business Wire
Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness in Real-World and Clinical Settings at IDWeek 2023
October 11, 2023
From
Shionogi USA
Via
Business Wire
IDWeek 2023: Shionogi Presents New Real-World Evidence Demonstrating Effectiveness of Earlier Treatment with Fetroja® (cefiderocol) in Appropriate Patients
October 11, 2023
From
Shionogi USA
Via
Business Wire
Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA
September 27, 2023
From
Shionogi USA
Via
Business Wire
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
September 18, 2023
From
Shionogi USA
Via
Business Wire
Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections
September 12, 2023
From
Shionogi USA
Via
Business Wire
IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease
September 07, 2023
From
Shionogi USA
Via
Business Wire
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
June 26, 2023
From
Shionogi USA
Via
Business Wire
Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
June 09, 2023
From
Shionogi USA
Via
Business Wire
ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® / Fetroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens
April 17, 2023
From
Shionogi USA
Via
Business Wire
Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19
April 04, 2023
From
Shionogi USA
Via
Business Wire
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data and Exploratory Long COVID Data at CROI
February 21, 2023
From
Shionogi USA
Via
Business Wire
Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja® (cefiderocol) Against Treatment Resistant Bacterial Infections at IDWeek 2022
October 19, 2022
From
Shionogi USA
Via
Business Wire
Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries
June 14, 2022
From
Shionogi USA
Via
Business Wire
Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership
June 01, 2022
From
Shionogi USA
Via
Business Wire
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
April 23, 2022
From
Shionogi USA
Via
Business Wire
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
October 21, 2021
From
Shionogi USA
Via
Business Wire
Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETROJA® (cefiderocol) Against Gram-Negative Pathogens
September 28, 2021
From
Shionogi USA
Via
Business Wire
Shionogi Strengthens U.S. Executive Leadership Team to Support Growth
May 03, 2021
From
Shionogi USA
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.